Finn
TAK Healthcare · Large cap · Japan · Drug pipeline · Thesis updated November 1, 2026

Pipeline victories accelerate Takeda despite brand pricing pressure

01 Running thesis

A cleaner handoff with new hurdles

Takeda is in the middle of a hard handoff. Older products are fading, led by VYVANSE after generic copies entered the market. At the same time, newer medicines are growing. Management is formally retiring the old Growth and Launch category to refocus the company purely on New Launches and Core In-line Brands. The headwind from VYVANSE generic erosion is steadily tapering off, and a major cost efficiency program has successfully offset the gross profit impact.

ENTYVIO is the key bridge. The Pen version now has access with all three large US pharmacy benefit managers, with more than 80 percent commercial coverage. That helps US growth stabilize after earlier payer access problems. However, the brand recently saw a US sales decline driven by a negative pricing mix, despite underlying demand growth.

The bull case rests on the pipeline, which has translated into concrete launch execution. ORZEYFUL is now launched in Japan and China for narcolepsy, though a missed listing window will delay the full commercial rollout in China until January 2028. MIMRYLO launched in the US for polycythemia vera in August with a favorable recommendation. Zasocitinib was accepted for priority review by the FDA for psoriasis.

New clinical risks have emerged. Zasocitinib recently failed to show a clean dose response in a Phase II ulcerative colitis trial, clouding the narrative for expanding the drug into inflammatory bowel disease. Open questions now center on the initial US commercial uptake metrics for the newest products and the duration of Albumin demand softening in China.

Oct 2026→ORZEYFUL and MIMRYLO moved into commercial launch. However, a trial for zasocitinib in ulcerative colitis failed to show a clean dose response, complicating its clinical path.
Jul 2026→The late-stage pipeline delivered major wins, including ORZEYFUL approval in China. However, ENTYVIO saw a US sales decline due to negative pricing, and ORZEYFUL's full China launch was delayed to 2028.
Jun 2026→Takeda announced it is discontinuing its cell therapy efforts to prioritize its portfolio. Management also clarified that Albumin demand softness in China is due to government guidelines.
May 2026▲Takeda gave more detail on the transition plan, with three major launch candidates expected within 12 months. The update also showed the cost of the reset, including JPY 170 billion of expected restructuring cost.
Jan 2026▲ENTYVIO Pen access improved sharply, reaching all three large US PBMs and more than 80 percent commercial coverage. Management also said operating expense discipline fully offset the VYVANSE impact.
Oct 2025→The VYVANSE generic hit appeared past its peak, but ENTYVIO growth expectations and foreign exchange both weighed on the near-term outlook.
May 2025→Takeda entered the final year of major VYVANSE erosion while facing a JPY 130 billion US rebate headwind. Positive rusfertide Phase 3 data strengthened the pipeline case.
Jan 2025▲Guidance improved as Growth and Launch products stayed strong and VYVANSE erosion was slower than expected. Takeda also announced a planned CEO transition for June 2026.
02 Business model

Patents fund the pipeline

Takeda makes money by selling prescription drugs, vaccines, and plasma-derived therapies. Many of its best products are protected by patents, special manufacturing know-how, or strong doctor use. When protection ends, generic or biosimilar rivals can take share and cut prices fast.

The company is trying to replace older revenue with a fresh wave of assets. The new focus is on products that are within five years of launch, ensuring the pipeline constantly refreshes the top line.

Cost cuts are a major part of the model right now. Management is using an enterprise-wide efficiency program and expects core operating profit margins to improve by 100 to 250 basis points annually from FY2025. A basis point is one one-hundredth of a percentage point.

There is a tradeoff. Takeda is cutting costs while preparing major launches. The company is actively executing on the upcoming launches of key late-stage pipeline assets. In its core Plasma-Derived Therapies business, Takeda is expanding its infrastructure through strategic partnerships, such as a collaboration with the Indonesian government to build plasma donation centers.

03 Product portfolio

What carries the story

Growth engine

ENTYVIO

ENTYVIO treats inflammatory bowel disease. Its Pen version has broad US commercial coverage, reducing access risk, but negative pricing mix is pressuring sales.

Cash cow

VYVANSE

VYVANSE treats ADHD and is facing generic erosion. Takeda lost significant revenue here, but the worst pressure is tapering off.

Steady

Plasma-Derived Therapies

This business sells therapies made from human plasma. Subcutaneous immunoglobulin is growing well, but Albumin demand in China is challenged by new government guidelines.

Option

QDENGA

QDENGA is a dengue vaccine. It is accelerating rapidly, driven primarily by demand in Brazil.

Option

ORZEYFUL

ORZEYFUL is a narcolepsy type 1 drug. It launched in Japan and China, with a US launch pending scheduling.

Option

MIMRYLO

MIMRYLO, also known as rusfertide, is aimed at polycythemia vera. Takeda launched it in the US with favorable clinical guidelines.

Option

Zasocitinib

Zasocitinib is a psoriasis drug candidate under FDA priority review, though a lack of dose response in a recent trial complicates its expansion into other diseases.

04 Business segments

Where revenue comes from

Gastroenterology31%modest
Plasma-Derived Therapies24%modest
Rare Diseases17%modest
Oncology13%modest
Neuroscience9%declining
Vaccines1%growing fast
Other5%declining

The mix uses fiscal year 2025 business-area revenue for the year ended March 31, 2026. Gastroenterology is the largest area.

05 Risk factors

What could break it

ENTYVIO competition and pricing

High impact · High odds

ENTYVIO is central to the bridge from old drugs to new launches. The brand is seeing US sales contract under a negative pricing mix. Biosimilar rivals are an emerging risk in Europe.

We watchWatch US pricing commentary, European biosimilar approvals, and ENTYVIO growth in Crohn's disease.

Launch cycle execution

High impact · Medium odds

ORZEYFUL, MIMRYLO, and zasocitinib carry a large part of the bull case. Regulatory hurdles can slow momentum, as seen with ORZEYFUL missing the China listing window.

We watchWatch FDA scheduling, launch timing, labels, and first-year sales metrics.

Albumin softness in China

Medium impact · High odds

Takeda's plasma business is mixed. Albumin demand in China softened, driven by new government utilization guidelines. This is a longer-term structural headwind.

We watchWatch Albumin growth, China demand commentary, and PDT full-year guidance.

US pricing pressure

Medium impact · High odds

US Medicare Part D redesign and 340B expansion create near-term gross-to-net pressure, meaning more rebates and discounts come off list prices.

We watchWatch US gross-to-net commentary, IRA drug selection lists, and changes in Medicare exposure.

Clinical expansion setbacks

Medium impact · Medium odds

Clinical risk has emerged around zasocitinib's potential expansion into inflammatory bowel disease. A Phase II trial in ulcerative colitis failed to show a clean dose response.

We watchWatch for upcoming Crohn's disease data and further trial results.
06 Quick answers

In one breath

Why is Takeda stock tied to VYVANSE?

VYVANSE used to be a major profit source, but generic versions are taking share. The sharpest part of the erosion has passed.

What is Takeda's most important drug?

ENTYVIO is the key product to watch because it is large, still growing, and central to the transition plan. Future biosimilar competition is a major risk.

What are Takeda's next big launches?

The main late-stage launches are ORZEYFUL for narcolepsy, MIMRYLO for polycythemia vera, and zasocitinib for psoriasis. The first two are already launching in key markets.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 1, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Takeda FY2026 Q2 Earnings Call Transcript
  2. Takeda FY2026 Q1 Earnings Call Transcript
  3. Takeda FY2026 Form 20-F Filing
08 Explore the industry

Comparable Drug Manufacturers - Specialty & Generic companies

Companies near Takeda Pharmaceutical Company Limited in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

Get started with Finn today